Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion Nets $200K SBIR Grant

NEW YORK (GenomeWeb News) – Fluxion Biosciences has won a Small Business Innovation Research grant from the National Cancer Institute, which it plans to use to continue developing a platform for diagnosing cancer early in its progression, the company said today.

The company specifically plans to use the $200,000 grant to develop its microfluidic systems for magnetic-bead based cell separations and other instruments to detect tumor cells circulating in the bloodstream that appear in low concentrations in the early stages of cancer. These circulating tumor cells detach from primary tumors as part of the metastasizing process, and a diagnostic tool for these cells may provide monitoring for a patient's condition and response to therapy.

The technology also will be designed to detect other rare cell types, said Fluxion.

Filed under

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.